Recent Finacing
Recent Raise
RxMP Therapeutics develops RMP-HPE, a red blood cell derived microparticle hemostatic agent licensed from the University of Miami, for surgical, trauma, obstetric, and dental bleeding management.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at RxMP Therapeutics.
